Skip to content
Book a demo
Life Sciences Intelligence · 2026

Small Molecule
GLP-1R Agonists
Market Landscape

Who's winning, who's out, and what happens next. 
 
e (1)-1
📄 What's inside

The GLP-1 race is intensifying. Novo Nordisk is deploying aggressive Wegovy pricing to defend US market share while closing a $2.1B deal with Vivtex for oral obesity biologics. Meanwhile, Verdiva Bio has completed enrollment in its Ph2b trial of oral GLP-1 candidate VRB-101. In this crowded field, best-in-class efficacy, patient adherence, and robust IP protection have never mattered more.

This report breaks down what you need to know across three chapters:

Pfizer & Eli Lilly's GLP Move
Implications

Danuglipron's DILI-driven termination, Pfizer's full exit from the small molecule space, and what Orforglipron's Phase III results mean for oral GLP-1R competition in 2025 and beyond.

Clinical Results &
Standard Therapies

Analysis of 174 GLP-1R clinical results globally, patent status of key drugs through 2045, and deep-dives on Pfizer, Eli Lilly, AstraZeneca, Gilead, and Amgen's MariTide programme.

Strategic Summary &
Outlook

Why always-on patent surveillance and FTO checks are mission-critical, how to win on safety as well as efficacy, and why APAC will define the next competitive phase.

📅  2025 MARKET TIMELINE

Every move that mattered, month over month

Viking TX logo
January
Viking Therapeutics
Begins Ph2 VENTURE-Oral trial of VK2735 in obesity — one of the most anticipated oral GLP-1 readouts of the year.

 

Verdiva bio logo
January
Verdiva Bio
$410M
Launches with $410M debut; weekly oral GLP-1 receptor agonist targeting obesity.

 

Roche Zeal
March
Zeals / Roche 
$5.3B
Deal signed for amylin analogue petrelintide — one of the largest GLP-1 adjacent deals on record.

 

Eli Lily logo
April
Eli Lilly
Oral GLP-1 shows injectable-level efficacy in Phase III diabetes trial. Orforglipron submission imminent.

 

Pfizer
April
Pfizer
Drops PF-07976016 over confirmed liver injury case. Full withdrawal from small molecule GLP-1 space.

 

novo-septerna
April
Pfizer
$2.2B
Drops PF-07976016 over confirmed liver injury case. Full withdrawal from small molecule GLP-1 space.

 

fractyl health logo
May
Fractyl Health
Launches Rejuva — first-in-human pancreas-targeted GLP-1 gene therapy. A new modality enters the race.

 

Camurus_Logo.svg
June
Camurus
 $870M
Launches Rejuva — first-in-human pancreas-targeted GLP-1 gene therapy. A new modality enters the race.

 

Viatris.svg
July
Viatris
Clears Wegovy patent hurdle with Novo Nordisk — biosimilar pathway officially opens.

 

Eli Lily logo
August/September
Eli Lilly
Orforglipron nails 3rd Phase III trial. Global regulatory submissions now in preparation.

 

Mindrank AI
August/September
Mindrank AI
Positive 12-week data for MDR-001 — an AI-designed oral GLP-1. A new class of developer enters the race.

 

DOWNLOAD THE REPORT
Group 1912060037
 
âš¡Powered by

This report was built
with Synapse by Patsnap

Through connected datasets across IP, drug discovery, clinical through to commercial areas, together with the proprietary AI and pharma-trained GPT, Synapse helps Therapeutic, Search & Evaluation and Competitive Intelligence leads to extrapolate unparalleled intelligence to make informed decisions to drive R&D and clinical investments with confidence.

  •  

    Normalize the noise: Standardized drug-disease-target ontologies for precise analysis.

  • Break down silos: All-in-one platform for R&D, IP, CI and BD teams to accelerate decisions.

  • Surface early signals: Monitor early-stage assets and global competitive shifts in real-time.

  • Invest with certainty: Seamlessly connect patent, clinical, drug, and deal data to de-risk every investment.